PFRM3.SA

Profarma Distribuidora de Produtos Farmacêuticos S.A. [PFRM3.SA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

PFRM3.SA Stock Summary

Earnings have grown 10.82% per last year.

PFRM3.SA's dividend payments are well covered by cash flows with cash payout ratio of 68.52%.

Earnings are expected to fall -43.79% next year

PFRM3.SA has less than 1 year of cash runway

In the News

PFRM3.SA Financial details

Company Rating

Buy

Market Cap

659.65M

Income

69.79M

Revenue

8.66B

Book val./share

10.18

Cash/share

1.58

Dividend

0.39

Dividend %

7.24%

Employees

7.08K

Optionable

Shortable

Yes

Earnings

08 May 2024

P/E

14.23

Forward P/E

PEG

-9.8

P/S

0.08

P/B

0.52

P/C

3.41

P/FCF

1.93

Quick Ratio

0.79

Current Ratio

1.37

Debt / Equity

0.7

LT Debt / Equity

0.37

EPS (TTM)

0.56

EPS next Y

EPS next Q

EPS this Y

-13.64%

EPS next Y

EPS next 5Y

-4.29%

EPS last 5Y

42.3%

Revenue last 5Y

12.53%

Revenue Q/Q

-3.94%

EPS Q/Q

-11.54%

SMA20

-1.81%

SMA50

14.08%

SMA100

19.34%

Inst Own

Inst Trans

ROA

ROE

ROC

0.09%

Gross Margin

15%

Oper. Margin

Profit Margin

Payout

Shs Outstand

122.61M

Shs Float

40.46M

Target Price

52W Range

3.04-6.15

52W High

-10.33%

52W Low

+79.33%

RSI

48.5

Rel Volume

1.39

Avg Volume

231.17K

Volume

320.7K

Perf Week

-1.1%

Perf Month

-7.88%

Perf Quarter

39.02%

Perf Half Y

44.62%

Beta

1.296

Volatility

0.06%, 0.12%

Prev Close

-2.71%

Price

5.38

Change

1.13%

PFRM3.SA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	39.16	44.71	52.31	63.75	70.64
Net income per share	0.1	0.43	0.64	0.66	0.57
Operating cash flow per share	1.04	0.32	0.88	1.03	1.16
Free cash flow per share	0.81	-0.05	0.77	0.94	0.49
Cash per share	1.88	3.22	1.58	1.13	1.58
Book value per share	8.19	8.53	8.86	9.71	10.18
Tangible book value per share	3.07	6.61	6.95	7.27	7.16
Share holders equity per share	8.19	8.53	8.86	9.71	10.18
Interest debt per share	6.21	7.89	8.34	9.57	8.49
Market cap	793.29M	747.93M	723.4M	426.69M	652.29M
Enterprise value	1.24B	1.28B	1.48B	1.27B	1.6B
P/E ratio	66.23	14.29	9.25	5.28	9.27
Price to sales ratio	0.17	0.14	0.11	0.05	0.08
POCF ratio	6.25	19.01	6.72	3.38	4.59
PFCF ratio	7.97	-128.51	7.69	3.68	10.77
P/B Ratio	0.79	0.71	0.67	0.36	0.52
PTB ratio	0.79	0.71	0.67	0.36	0.52
EV to sales	0.26	0.23	0.23	0.16	0.18
Enterprise value over EBITDA	5.09	6.33	5.97	3.46	4.07
EV to operating cash flow	9.74	32.45	13.77	10.03	11.28
EV to free cash flow	12.42	-219.39	15.76	10.95	26.47
Earnings yield	0.02	0.07	0.11	0.19	0.11
Free cash flow yield	0.13	-0.01	0.13	0.27	0.09
Debt to equity	0.67	0.86	0.87	0.86	0.7
Debt to assets	0.21	0.24	0.23	0.23	0.18
Net debt to EBITDA	1.82	2.62	3.06	2.3	2.41
Current ratio	1.33	1.61	1.5	1.52	1.45
Interest coverage	1.58	1.49	1.6	1.53	1.46
Income quality	5.89	1.19	2.21	1.6	2.02
Dividend Yield	0	0	0.04	0	0.05
Payout ratio	0	0	0.37	0	0.44
Sales general and administrative to revenue	0.03	0.02	0.02	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.2	0.17	0.15	0.14	0.13
Capex to operating cash flow	-0.22	-1.15	-0.13	-0.08	-0.57
Capex to revenue	-0.01	-0.01	0	0	-0.01
Capex to depreciation	-0.29	-0.44	-0.11	-0.08	-0.55
Stock based compensation to revenue	0	0	0	0	0
Graham number	4.24	9.05	11.27	12.01	11.47
ROIC	0.04	0.08	0.08	0.1	0.1
Return on tangible assets	0	0.02	0.02	0.02	0.02
Graham Net	-6.36	-4.85	-6.87	-7.57	-8.97
Working capital	519.87M	940.29M	865.12M	1.02B	1.09B
Tangible asset value	375.87M	810.75M	851.56M	891.12M	921.12M
Net current asset value	-82.96M	158.3M	25M	126.09M	140.47M
Invested capital	0.67	0.86	0.87	0.86	0.7
Average receivables	480.01M	1.07B	1.24B	1.43B	1.67B
Average payables	1B	1.1B	1.24B	1.42B	1.69B
Average inventory	846.45M	900.79M	994.24M	1.16B	1.38B
Days sales outstanding	72.98	78.56	74.35	72.82	75.34
Days payables outstanding	95.35	88.64	88.37	82.47	92.61
Days of inventory on hand	80.64	69.93	71.91	67.61	75.66
Receivables turnover	5	4.65	4.91	5.01	4.84
Payables turnover	3.83	4.12	4.13	4.43	3.94
Inventory turnover	4.53	5.22	5.08	5.4	4.82
ROE	0.01	0.05	0.07	0.07	0.06
Capex per share	-0.22	-0.37	-0.11	-0.09	-0.67

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	17.09	16.5	17.4	18.74	18
Net income per share	0.04	-0.05	0.12	0.26	0.23
Operating cash flow per share	1.47	0.32	-2.37	3.71	0.4
Free cash flow per share	1.24	0.24	-2.49	3.54	0.11
Cash per share	1.13	1.01	0.98	1.46	1.58
Book value per share	9.71	9.66	9.78	10.29	10.18
Tangible book value per share	7.27	7.22	7.34	7.63	7.16
Share holders equity per share	9.71	9.66	9.78	10.29	10.18
Interest debt per share	8.65	8.9	11.58	9.02	7.43
Market cap	426.69M	400.94M	483.09M	476.96M	652.29M
Enterprise value	1.27B	1.29B	1.71B	1.37B	1.6B
P/E ratio	23.37	-17.86	8.15	3.71	5.74
Price to sales ratio	0.2	0.2	0.23	0.21	0.3
POCF ratio	2.37	10.11	-1.67	1.05	13.42
PFCF ratio	2.81	13.9	-1.58	1.1	48
P/B Ratio	0.36	0.34	0.4	0.38	0.52
PTB ratio	0.36	0.34	0.4	0.38	0.52
EV to sales	0.6	0.64	0.8	0.6	0.73
Enterprise value over EBITDA	17.51	20.15	18.08	12.71	15.94
EV to operating cash flow	7.03	32.46	-5.9	3.02	32.96
EV to free cash flow	8.34	44.64	-5.6	3.16	117.9
Earnings yield	0.01	-0.01	0.03	0.07	0.04
Free cash flow yield	0.36	0.07	-0.63	0.91	0.02
Debt to equity	0.86	0.89	1.15	0.85	0.7
Debt to assets	0.23	0.22	0.3	0.23	0.18
Net debt to EBITDA	11.62	13.88	12.97	8.29	9.45
Current ratio	1.52	1.38	1.4	1.37	1.45
Interest coverage	1.02	0.77	1.61	2.07	1.61
Income quality	217.57	-4.79	-13.2	12.57	1.71
Dividend Yield	0	0.05	0	0	0.05
Payout ratio	0	-3.34	0	0	1.1
Sales general and administrative to revenue	-0.05	0	0.02	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.14	0.13	0.13	0.13	0.13
Capex to operating cash flow	-0.16	-0.27	0.05	-0.05	-0.72
Capex to revenue	-0.01	-0.01	-0.01	-0.01	-0.02
Capex to depreciation	-0.81	-0.31	-0.41	-0.54	-0.91
Stock based compensation to revenue	0	0	0	0	0
Graham number	2.85	3.15	5.16	7.79	7.29
ROIC	0.1	0.01	0.02	0.02	0.03
Return on tangible assets	0	0	0	0.01	0.01
Graham Net	-7.57	-9.1	-8.15	-7.8	-8.97
Working capital	1.02B	950.41M	932.3M	887.28M	1.09B
Tangible asset value	891.12M	885.69M	900.21M	935.62M	921.12M
Net current asset value	126.09M	127.85M	152.93M	180.39M	140.47M
Invested capital	0.86	0.89	1.15	0.85	0.7
Average receivables	1.53B	1.64B	1.72B	1.74B	1.76B
Average payables	1.4B	1.7B	1.63B	1.54B	1.8B
Average inventory	1.2B	1.39B	1.45B	1.37B	1.46B
Days sales outstanding	66.97	76.09	73.23	67.98	72.91
Days payables outstanding	75.1	98.32	68.06	79.01	95.21
Days of inventory on hand	61.57	79.91	67.74	63.89	77.79
Receivables turnover	1.34	1.18	1.23	1.32	1.23
Payables turnover	1.2	0.92	1.32	1.14	0.95
Inventory turnover	1.46	1.13	1.33	1.41	1.16
ROE	0	0	0.01	0.03	0.02
Capex per share	-0.23	-0.09	-0.12	-0.17	-0.29

PFRM3.SA Dividend History

PFRM3.SA Frequently Asked Questions

What is Profarma Distribuidora de Produtos Farmacêuticos S.A. stock symbol ?

Profarma Distribuidora de Produtos Farmacêuticos S.A. is a BR stock , located in Rio de janeiro of Rj and trading under the symbol PFRM3.SA

What is Profarma Distribuidora de Produtos Farmacêuticos S.A. stock quote today ?

Profarma Distribuidora de Produtos Farmacêuticos S.A. stock price is $5.38 today.

Is Profarma Distribuidora de Produtos Farmacêuticos S.A. stock public?

Yes, Profarma Distribuidora de Produtos Farmacêuticos S.A. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 231.17K
Market Capitalization 659.65M
Employee 7.08K
CEO Mr. Sammy Birmarcker
Headquarters Rio De Janeiro,RJ,BR
IPO Date 2006-10-26
Website https://www.profarma.com.br

Profarma Distribuidora de Produtos Farmacêuticos S.A., together with its subsidiaries, engages in the distribution and retail sale of pharmaceutical and hospital products in Brazil. The company operates through Distribution, and Retail segments. It provides branded medicines, generic drugs, and over-the-counter (OTC) medicines; personal hygiene, beauty, and cosmetic products, such as shampoos, conditioners, treatment creams and hair dyes, diapers and children's products, soaps , deodorants, oral care products, sunscreens, male products, cosmetics, makeup and skin products, and others; and hospital products, including injectable and infusion drugs for oncology, endocrinology, rheumatology, infectology, hematology, and other specialties. The company also offers vaccines for influenza, HPV, meningitis, hepatitis, chickenpox, dengue, and other diseases; special medicines intended for the treatment of rare and complex diseases; exclusive hygiene and beauty products, vitamins, and workshops products under the Nº21, GOnutri, and Bem Básico brands; and convenience products, including food products, pressure gauges, scales, and related products. In addition, it provides complementary services, such as promotional and logistical support, implementation of promotional campaigns, product recall, development of customized projects to offer laboratories solutions, and management of clinical procedures. As of December 31, 2019, the company operated eleven distribution centers located in the states of Alagoas, Bahia, Espírito Santo, Goiás, Minas Gerais, Paraíba, Paraná, Pernambuco, Rio Grande do Sul, Rio de Janeiro, and São Paulo, as well as approximately 196 stores in the states of Rio de Janeiro, Goiás, Tocantins, Mato Grosso, and Distrito Federal under the Drogarias Tamoio, Drogasmil, Farmalife, and Rede Rosário brands. The company was founded in 1961 and is headquartered in Rio de Janeiro, Brazil.